Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells
about
NKG2D ligands as therapeutic targetsEngineered T cells for cancer treatmentNKG2D CARs as cell therapy for cancer.An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.The immune microenvironment of myelomaThe Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic MalignanciesT Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond.Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Adoptive immunotherapy for cancer.Immunotherapeutic approaches to treat multiple myelomaNKG2D signaling in cancer immunosurveillance.Adoptive Cell Therapy in Multiple Myeloma.Novel Immunotherapies for Multiple Myeloma.Exploiting natural killer group 2D receptors for CAR T-cell therapy.Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myelomaPractical considerations for chimeric antigen receptor design and delivery.Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy.
P2860
Q27014888-70DF2C8F-7070-4CC9-BA52-B50DD7850574Q33578792-63A0943B-F4A3-4B4C-A9F3-AC858347F200Q33595873-BE764B4A-D94E-47EA-9118-D051C6769117Q34786615-95BA9033-3443-47AC-9C6B-814E5313C166Q35603152-D4DF23C7-A36B-437D-8A7C-D3504D8B6F44Q36547199-078C6195-D36B-4659-8EA1-CEDE7B13DB39Q36757142-321CFCD2-0493-4D3B-A244-E1A02293C465Q36845643-64F86094-63B5-4DF6-959A-D32C49B467B4Q36845800-E663BC71-1561-4DE4-A659-03FD6A0FA8D1Q36980241-B2596E2F-8FAE-4D53-A7F3-6AFEE55947EDQ37169138-C40B7361-1504-44F8-887D-8F01394634D8Q38008379-3D8BFEF6-04EB-4418-AFC0-6B2B37FB48A6Q38170496-489BAD75-3193-4B73-ACC9-1BEDFFD630BAQ38171067-506B0152-1B08-4F69-901C-BBD33BEF5E51Q38194944-67C8F6BA-7268-48B5-A0B2-3870A86D0059Q38635138-DE7AD547-55A5-45DA-9A2E-D0DC217BD434Q38640444-3D50A793-16BD-405B-8755-7B8A4D7E0A10Q38671184-5F021714-32D4-4C4B-9675-7ADC4D9C25EFQ38730881-81FFEF66-851D-4A33-B386-8AAACF4DC840Q38830813-15B1868A-D85D-4C86-B24B-87F5D1B1F1B4Q38849985-AE8FC615-F85D-4744-B3C9-A470559D8340Q38987239-153C4C0C-C06B-4351-8B12-B4E84E1D652CQ42378344-9C7143B8-B012-4870-8C4A-7817530EDDCEQ45868559-A48E5A23-BB55-4380-80AB-3FECB0648FA3Q47111488-0A893C22-8FDA-4FED-815E-E48B3D644E24Q47159409-224CFDA9-D23B-4070-9750-C0D55827CD46Q47216941-0633D651-F574-493C-9D35-5A710FA3FFE3Q47849932-E018564D-D8E2-47E5-9EE7-F45FECD98B8AQ50199706-A4AF05CE-0040-4442-B695-BF7A041E6603
P2860
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@ast
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@en
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@nl
type
label
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@ast
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@en
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@nl
prefLabel
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@ast
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@en
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@nl
P2093
P2860
P356
P1433
P1476
Treatment of multiple myeloma ...... 2D receptor-expressing T cells
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2010.174
P577
2011-01-06T00:00:00Z
P5875
P6179
1024131213